These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 31566275)

  • 1. Nanomedicine-Based Immunotherapy for the Treatment of Cancer Metastasis.
    Zhang P; Zhai Y; Cai Y; Zhao Y; Li Y
    Adv Mater; 2019 Dec; 31(49):e1904156. PubMed ID: 31566275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastases in immune-mediated dormancy: a new opportunity for targeting cancer.
    Romero I; Garrido F; Garcia-Lora AM
    Cancer Res; 2014 Dec; 74(23):6750-7. PubMed ID: 25411345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
    Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH
    Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges.
    Martin JD; Cabral H; Stylianopoulos T; Jain RK
    Nat Rev Clin Oncol; 2020 Apr; 17(4):251-266. PubMed ID: 32034288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective.
    Liu J; Bai Y; Li Y; Li X; Luo K
    EBioMedicine; 2024 Sep; 107():105301. PubMed ID: 39178747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoscale artificial antigen presenting cells for cancer immunotherapy.
    Rhodes KR; Green JJ
    Mol Immunol; 2018 Jun; 98():13-18. PubMed ID: 29525074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of individualized anti-metastasis strategies by engineering nanomedicines.
    He Q; Guo S; Qian Z; Chen X
    Chem Soc Rev; 2015 Oct; 44(17):6258-6286. PubMed ID: 26056688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-Microenvironment-Responsive Nanomedicine for Enhanced Cancer Immunotherapy.
    Peng S; Xiao F; Chen M; Gao H
    Adv Sci (Weinh); 2022 Jan; 9(1):e2103836. PubMed ID: 34796689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy.
    Phuengkham H; Ren L; Shin IW; Lim YT
    Adv Mater; 2019 Aug; 31(34):e1803322. PubMed ID: 30773696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
    Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
    Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy.
    Zhao YD; Muhetaerjiang M; An HW; Fang X; Zhao Y; Wang H
    Biomaterials; 2021 Jan; 268():120552. PubMed ID: 33307365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune cell promotion of metastasis.
    Kitamura T; Qian BZ; Pollard JW
    Nat Rev Immunol; 2015 Feb; 15(2):73-86. PubMed ID: 25614318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Control of Metastasis by NK Cells.
    López-Soto A; Gonzalez S; Smyth MJ; Galluzzi L
    Cancer Cell; 2017 Aug; 32(2):135-154. PubMed ID: 28810142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploiting in situ antigen generation and immune modulation to enhance chemotherapy response in advanced melanoma: A combination nanomedicine approach.
    Lu Y; Wang Y; Miao L; Haynes M; Xiang G; Huang L
    Cancer Lett; 2016 Aug; 379(1):32-8. PubMed ID: 27235608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
    Yang J; Zhang C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory nanomedicine for colorectal cancer treatment: a landscape to be explored?
    Silveira MJ; Castro F; Oliveira MJ; Sarmento B
    Biomater Sci; 2021 May; 9(9):3228-3243. PubMed ID: 33949441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokines in immunogenic cell death: Applications for cancer immunotherapy.
    Showalter A; Limaye A; Oyer JL; Igarashi R; Kittipatarin C; Copik AJ; Khaled AR
    Cytokine; 2017 Sep; 97():123-132. PubMed ID: 28648866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.
    Zanganeh S; Spitler R; Hutter G; Ho JQ; Pauliah M; Mahmoudi M
    Immunotherapy; 2017 Sep; 9(10):819-835. PubMed ID: 28877626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.